Literature DB >> 15172044

Infliximab treatment of rheumatoid arthritis.

Sir Ravinder Maini1.   

Abstract

Infliximab was the first anti-TNF agent used to treat rheumatoid arthritis to provide proof of concept of the role of TNF-alpha in this condition. It has become widely used since, principally as an effective treatment in combination with methotrexate, but also as monotherapy for the treatment of Crohn's disease, ankylosing spondylitis,and psoriatic arthritis. The benefits of infliximab in controlling signs and symptoms, improving quality of life, preventing structural joint damage, and possible healing of bone provide an important option for the treatment of rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15172044     DOI： 10.1016/j.rdc.2004.01.009

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  8 in total

Review 1.  Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy.

Authors:  D S Rampton
Journal:  Gut       Date:  2005-08-19       Impact factor: 23.059

2.  Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study.

Authors:  M S Heiberg; E Rødevand; K Mikkelsen; C Kaufmann; A Didriksen; P Mowinckel; T K Kvien
Journal:  Ann Rheum Dis       Date:  2006-05-05       Impact factor: 19.103

Review 3.  Biologics in juvenile idiopathic arthritis: a narrative review.

Authors:  Federica Vanoni; Francesca Minoia; Clara Malattia
Journal:  Eur J Pediatr       Date:  2017-07-20       Impact factor: 3.183

4.  Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial.

Authors:  H Al-Rayes; R Al-Swailem; M Al-Balawi; N Al-Dohayan; S Al-Zaidi; M Tariq
Journal:  Rheumatol Int       Date:  2008-05-22       Impact factor: 2.631

Review 5.  Molecular medicine: promises, promises?

Authors:  Michael Steel
Journal:  J R Soc Med       Date:  2005-05       Impact factor: 18.000

6.  Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity.

Authors:  Bert Vander Cruyssen; Stijn Van Looy; Bart Wyns; Rene Westhovens; Patrick Durez; Filip Van den Bosch; Herman Mielants; Luc De Clerck; Ann Peretz; Michel Malaise; Leon Verbruggen; Nathan Vastesaeger; Anja Geldhof; Luc Boullart; Filip De Keyser
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

7.  Infliximab in the treatment of rheumatoid arthritis.

Authors:  A Perdriger
Journal:  Biologics       Date:  2009-07-13

8.  Derlin-1, as a Potential Early Predictive Biomarker for Nonresponse to Infliximab Treatment in Rheumatoid Arthritis, Is Related to Autophagy.

Authors:  Yongsong Cai; Ke Xu; Yirixiati Aihaiti; Zhijin Li; Qiling Yuan; Jing Xu; Haishi Zheng; Mingyi Yang; Bo Wang; Yanni Yang; Yin Yang; Peng Xu
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.